Page last updated: 2024-10-27

gabapentin and Apoplexy

gabapentin has been researched along with Apoplexy in 21 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"To describe the use of gabapentin for treatment of persistent or intractable hiccups in post-stroke patients."9.12Treatment of hiccups in stroke rehabilitation with gabapentin: A case series and focused clinical review. ( Fan, C; Got, T; MacNeill, H; Vivas, L, 2021)
"In summary, cohort Medicare patients with non-cancer pain beginning treatment with duloxetine had rates of AMI, stroke, and out-of-hospital mortality comparable to those who initiated gabapentin."8.31Duloxetine, Gabapentin, and the Risk for Acute Myocardial Infarction, Stroke, and Out-of-Hospital Death in Medicare Beneficiaries With Non-Cancer Pain. ( Chung, CP; Corriere, MA; Daniel, LL; Dickson, AL; Dupont, WD; Hall, K; Murray, KT; Nepal, P; Plummer, WD; Ray, WA; Stein, CM, 2023)
"Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome."7.71Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002)
"Gabapentin monotherapy was useful and safe for late poststroke ES."6.70Gabapentin in late-onset poststroke seizures. ( Alvarez-Sabín, J; Codina, A; Molina, CA; Montaner, J; Padró, L; Quintana, M; Rovira, R, 2002)
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain."5.43A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016)
"Treatment with gabapentin was initiated, with good results at 6-month follow-up."5.31Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus. ( Kothare, SV; Kulberg, AG; Pollack, P; Ravin, PD, 2000)
"To describe the use of gabapentin for treatment of persistent or intractable hiccups in post-stroke patients."5.12Treatment of hiccups in stroke rehabilitation with gabapentin: A case series and focused clinical review. ( Fan, C; Got, T; MacNeill, H; Vivas, L, 2021)
"In summary, cohort Medicare patients with non-cancer pain beginning treatment with duloxetine had rates of AMI, stroke, and out-of-hospital mortality comparable to those who initiated gabapentin."4.31Duloxetine, Gabapentin, and the Risk for Acute Myocardial Infarction, Stroke, and Out-of-Hospital Death in Medicare Beneficiaries With Non-Cancer Pain. ( Chung, CP; Corriere, MA; Daniel, LL; Dickson, AL; Dupont, WD; Hall, K; Murray, KT; Nepal, P; Plummer, WD; Ray, WA; Stein, CM, 2023)
"In patients with diabetic neuropathy who were prescribed gabapentin and pregabalin, there is an increased risk for heart failure, myocardial infarction, peripheral vascular disease, stroke, deep venous thrombosis, and pulmonary embolism with long-term use."4.12Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. ( Blankfield, RP; Davis, PB; Kaebler, DC; Pan, Y; Xu, R, 2022)
"Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome."3.71Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002)
"Gabapentin monotherapy was useful and safe for late poststroke ES."2.70Gabapentin in late-onset poststroke seizures. ( Alvarez-Sabín, J; Codina, A; Molina, CA; Montaner, J; Padró, L; Quintana, M; Rovira, R, 2002)
" Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing."2.66Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? ( Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020)
"Mycophenolic acid was detected in all cats."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Because of this cause we decided to treat intractable hiccups in patients with ischemic lesions of the medulla with a short course of gabapentin."2.42Gabapentin as a drug therapy of intractable hiccup because of vascular lesion: a three-year follow up. ( Antonello, RM; Bava, A; Cazzato, G; Moretti, R; Torre, P; Ukmar, M, 2004)
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain."1.43A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016)
" We performed unilateral ventralis caudalis deep brain stimulation combined with stereotactic bilateral cingulotomy to maximize the effects of treatment for 3 patients with intractable post-stroke pain."1.38Impact of ventralis caudalis deep brain stimulation combined with stereotactic bilateral cingulotomy for treatment of post-stroke pain. ( Chang, JW; Chang, WS; Kim, JP; Park, YS, 2012)
"Treatment with gabapentin was initiated, with good results at 6-month follow-up."1.31Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus. ( Kothare, SV; Kulberg, AG; Pollack, P; Ravin, PD, 2000)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (33.33)29.6817
2010's9 (42.86)24.3611
2020's5 (23.81)2.80

Authors

AuthorsStudies
Tedeschi, A1
Larson, MJE1
Zouridakis, A1
Mo, L1
Bordbar, A1
Myers, JM1
Qin, HY1
Rodocker, HI1
Fan, F1
Lannutti, JJ1
McElroy, CA1
Nimjee, SM1
Peng, J2
Arnold, WD1
Moon, LDF1
Sun, W3
Pan, Y1
Davis, PB1
Kaebler, DC1
Blankfield, RP1
Xu, R1
Corriere, MA1
Dickson, AL1
Daniel, LL1
Nepal, P1
Hall, K1
Plummer, WD1
Dupont, WD1
Murray, KT1
Stein, CM1
Ray, WA1
Chung, CP1
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B2
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J6
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z1
Wang, Y5
Hu, X1
Li, Z4
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y4
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Jia, Z1
Li, F1
Chen, X3
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Klein, P1
Friedman, A1
Hameed, MQ1
Kaminski, RM1
Bar-Klein, G1
Klitgaard, H1
Koepp, M1
Jozwiak, S1
Prince, DA1
Rotenberg, A1
Twyman, R1
Vezzani, A1
Wong, M1
Löscher, W1
Got, T1
Vivas, L1
Fan, C1
MacNeill, H1
Hu, R1
Feng, M1
Yao, W1
Zhang, C1
Wan, L1
Yang, F4
Fu, H2
Lu, YF2
Wang, XL1
Yang, Y2
Yu, YQ2
Wang, JS1
Costigan, M1
Chen, J2
Fleming, GF1
Esin, RG1
Sitnova, MA1
Esin, OR1
Batlle, L1
Mattie, R1
Irwin, R1
Li, CL1
He, T1
Wang, RR1
Chen, WH1
Yin, HL1
Kim, JP1
Chang, WS1
Park, YS1
Chang, JW1
Chen, B1
Stitik, TP1
Foye, PM1
Nadler, SF1
DeLisa, JA1
Alvarez-Sabín, J1
Montaner, J1
Padró, L1
Molina, CA1
Rovira, R1
Codina, A1
Quintana, M1
Yen, HL1
Chan, W1
Moretti, R1
Torre, P1
Antonello, RM1
Ukmar, M1
Cazzato, G1
Bava, A1
Choudhuri, I1
Sarvananthan, N1
Gottlob, I1
Lalonde, RL1
Kowalski, KG1
Hutmacher, MM1
Ewy, W1
Nichols, DJ1
Milligan, PA1
Corrigan, BW1
Lockwood, PA1
Marshall, SA1
Benincosa, LJ1
Tensfeldt, TG1
Parivar, K1
Amantea, M1
Glue, P1
Koide, H1
Miller, R1
Kothare, SV1
Pollack, P1
Kulberg, AG1
Ravin, PD1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262]Phase 230 participants (Actual)Interventional2019-07-19Completed
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]8 participants (Actual)Interventional2009-11-30Terminated (stopped due to PI left institution)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for gabapentin and Apoplexy

ArticleYear
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
    Epilepsia, 2020, Volume: 61, Issue:3

    Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Cef

2020
Treatment of hiccups in stroke rehabilitation with gabapentin: A case series and focused clinical review.
    Topics in stroke rehabilitation, 2021, Volume: 28, Issue:6

    Topics: Gabapentin; Hiccup; Humans; Quality of Life; Retrospective Studies; Stroke; Stroke Rehabilitation

2021
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials

2015
Gabapentin as a drug therapy of intractable hiccup because of vascular lesion: a three-year follow up.
    The neurologist, 2004, Volume: 10, Issue:2

    Topics: Acetates; Aged; Amines; Brain Stem; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists;

2004
Model-based drug development.
    Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:1

    Topics: Alzheimer Disease; Amines; Analgesics; Animals; Anticholesteremic Agents; Bridged Bicyclo Compounds,

2007

Trials

1 trial available for gabapentin and Apoplexy

ArticleYear
Gabapentin in late-onset poststroke seizures.
    Neurology, 2002, Dec-24, Volume: 59, Issue:12

    Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr

2002

Other Studies

14 other studies available for gabapentin and Apoplexy

ArticleYear
Harnessing cortical plasticity via gabapentinoid administration promotes recovery after stroke.
    Brain : a journal of neurology, 2022, 07-29, Volume: 145, Issue:7

    Topics: Animals; Axons; Gabapentin; Mice; Neuronal Plasticity; Pyramidal Tracts; Recovery of Function; Strok

2022
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.
    Cardiovascular diabetology, 2022, 09-01, Volume: 21, Issue:1

    Topics: Amines; Analgesics; Cardiovascular Diseases; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gab

2022
Duloxetine, Gabapentin, and the Risk for Acute Myocardial Infarction, Stroke, and Out-of-Hospital Death in Medicare Beneficiaries With Non-Cancer Pain.
    The Clinical journal of pain, 2023, 05-01, Volume: 39, Issue:5

    Topics: Aged; Chronic Pain; Duloxetine Hydrochloride; Gabapentin; Hospitals; Humans; Medicare; Myocardial In

2023
Alleviation of Mechanical Allodynia by 14,15-Epoxyeicosatrienoic Acid in a Central Poststroke Pain Model: Possible Role of Allopregnanolone and δ-Subunit-Containing Gamma-Aminobutyric Acid A Receptors.
    The journal of pain, 2019, Volume: 20, Issue:5

    Topics: 8,11,14-Eicosatrienoic Acid; Analgesics; Animals; Cerebral Hemorrhage; Disease Models, Animal; Gabap

2019
Post-stroke pain hypersensitivity induced by experimental thalamic hemorrhage in rats is region-specific and demonstrates limited efficacy of gabapentin.
    Neuroscience bulletin, 2014, Volume: 30, Issue:6

    Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-

2014
[The principles of pharmacotherapy of poststroke shoulder pain].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:5

    Topics: Amines; Amitriptyline; Anti-Inflammatory Agents; Clonidine; Cyclohexanecarboxylic Acids; Drug Therap

2015
A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report.
    PM & R : the journal of injury, function, and rehabilitation, 2016, Volume: 8, Issue:3

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Thera

2016
Gabapentinoid Insensitivity after Repeated Administration is Associated with Down-Regulation of the α(2)δ-1 Subunit in Rats with Central Post-Stroke Pain Hypersensitivity.
    Neuroscience bulletin, 2016, Volume: 32, Issue:1

    Topics: Amines; Analgesics; Animals; Blotting, Western; Calcium Channels; Cyclohexanecarboxylic Acids; Disea

2016
Successful amelioration of tinnitus in a stroke patient by low-dose gabapentin.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Amines; Audiometry, Pure-Tone; Basal Ganglia Hemorrhage; Cerebral Angiography; Cyclohexanecarboxylic

2012
Impact of ventralis caudalis deep brain stimulation combined with stereotactic bilateral cingulotomy for treatment of post-stroke pain.
    Stereotactic and functional neurosurgery, 2012, Volume: 90, Issue:1

    Topics: Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Deep Brain Stimulation;

2012
Central post-stroke pain syndrome: yet another use for gabapentin?
    American journal of physical medicine & rehabilitation, 2002, Volume: 81, Issue:9

    Topics: Acetates; Activities of Daily Living; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxyli

2002
An East-West approach to the management of central post-stroke pain.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 16, Issue:1

    Topics: Acetates; Acupuncture; Aged; Amines; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Secon

2003
Survey of management of acquired nystagmus in the United Kingdom.
    Eye (London, England), 2007, Volume: 21, Issue:9

    Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists;

2007
Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus.
    Pediatric neurology, 2000, Volume: 22, Issue:1

    Topics: Acetates; Adolescent; Age of Onset; Amines; Antiparkinson Agents; Basal Ganglia; Chorea; Cyclohexane

2000